Abstract 5P
Background
Axillary lymph node metastases from adenocarcinoma or poorly differentiated carcinoma of unknown primary (CUPAx) is a rare disease in women. This subgroup shares similar biological characteristics with stage II-III breast cancer and is named occult breast cancer (OBC). This study intended to examine the clinicopathological features of OBC and compared OBC genetically with axillary lymph node metastases from breast cancer (BCAx), investigating differences in their biological behavior.
Methods
We conducted the clinical and prognostic analysis of 58 OBC patients in West China Hospital spanning from 2009 to 2021. Gemonic profiling of 12 OBC patients and 16 BCAx patients was conducted by the FoundationOne CDx (F1CDx) platform, including 324 genes along with genomic features such as TMB and MSI. Moreover, we also compared the gene mutation spectrum and relevant pathways between the two groups and both TCGA and COSMIC databases.
Results
The majority of the 58 OBC patients were HR-/HER2- subtype. OBC patients had a higher expression of breast origin-related immunohistochemical markers, such as GATA3, GCDFP15, and CK5/6. Most patients received mastectomy combined radiotherapy (50Gy/25f). OBC had a favorable overall prognosis. Radiotherapy was the independent prognostic factor in multivariate analysis (HR=0.04, 95%CI=0.00-0.85, P=0.0390). In 28 samples and 401 TCGA-BRCA patients, IRS2 only mutated in OBC (33.33%) but amplified in BCAx (11.11%) and TCGA-BRCA (1.5%). Pathway analysis revealed that BCAx had more NOTCH pathway mutations than OBC, where NOTCH3 and GATA3 was highly amplified in OBC (16.67% vs. 0%) and BCAx (16.67% vs. 0%) respectively. GATA6 only had novel mutations in BCAx (31.25%) according to the COSMIC database. Enrichment analysis showed that OBC enriched more in mammary development and PML bodies than BCAx, but less in the positive regulation of kinase activity.
Conclusions
More active treatment methods could improve the prognosis of OBC. The differential mutation genes of OBC and BCAx might be associated with their respective biological behaviors like invasiveness and prognosis. The differences in NOTCH pathway and enrichment analysis might cause the occult lesions in the OBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (ZYJC18022 and ZYJC21017).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes
Presenter: Ambedkar Yadala
Session: Poster Display
Resources:
Abstract
299P - Sexual dysfunction assessment in longterm survivors of carcinoma cervix using LENT SOMA scale
Presenter: Niharika Sethi
Session: Poster Display
Resources:
Abstract
300P - Assessing ovarian function in Vietnamese cervical cancer patients who underwent ovary transposition prior to pelvic radiation therapy
Presenter: Cuong Nguyen
Session: Poster Display
Resources:
Abstract
301P - Correlation between cervical cancer recurrence after radiation therapy and vaginal microbiome
Presenter: Xiaoxian Xu
Session: Poster Display
Resources:
Abstract
302P - Expression of ERCC4 gene and its correlation with clinical and pathological parameters in cervical cancer
Presenter: Himanshu Mishra
Session: Poster Display
Resources:
Abstract
303P - Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy
Presenter: Hui Guo
Session: Poster Display
Resources:
Abstract
305P - A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study
Presenter: Yoshikazu Nagase
Session: Poster Display
Resources:
Abstract
306P - Adjuvant treatment and impact on relapse in stage IA uterine papillary serous and clear cell carcinomas: A single center retrospective study
Presenter: Sachin Khurana
Session: Poster Display
Resources:
Abstract
307P - Hormonal therapy vs combination chemotherapy in metastatic leiomyosarcomas: A systematic review
Presenter: Patricia Angel
Session: Poster Display
Resources:
Abstract
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract